NEW YORK, June 17, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Kythera Biopharmaceuticals, Inc. ("Kythera" or the "Company") (NASDAQ: KYTH) concerning the proposed acquisition of the Company by Allergan plc ("Allergan").
Under the terms of his offer, Allergan would acquire Kythera in a transaction valued at approximately $2.1 billion. Pursuant to the deal, Kythera stockholders would receive $60.00 in cash and Allergan common shares worth approximately $15.00, for a total consideration of approximately $75. According to Yahoo Finance, at least one analyst has set a target price for Kythera of $85.00 per share.
Our investigation concerns whether the Kythera board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own Kythera shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Benjamin I Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Email: [email protected]
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP